Novo Nordisk Raises FY23 Guidance, Now Sees Sales And Operating Profit Growth Of 27%-33% (Prior View 24%-30%) At Constant Currency
Portfolio Pulse from Benzinga Newsdesk
Novo Nordisk has raised its FY23 guidance, now expecting sales and operating profit growth of 27%-33% at constant currency, up from the previous estimate of 24%-30%. The growth reported in Danish kroner is expected to be 6 and 9 percentage points lower than at CER.
August 10, 2023 | 7:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novo Nordisk's raised FY23 guidance indicates a positive outlook for the company's financial performance, which could potentially lead to an increase in its stock price.
Novo Nordisk's raised guidance for FY23 suggests that the company is expecting stronger financial performance than previously anticipated. This positive outlook could potentially lead to increased investor confidence and a subsequent rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100